Invivoscribe

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Invivoscribe sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 1 currently recruiting 1 completed upper quartile by trial count

Invivoscribe: 3 sponsored US clinical trials, 1 recruiting.

Invivoscribe sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. The most-studied condition in this pipeline is Hematologic Diseases, with 1 trials.

Upper-quartile sponsor footprint

Invivoscribe sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

3 total, page 1 of 1

RECRUITING

The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research

NCT06222164
NOT YET RECRUITING

Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay

NCT06876571
COMPLETED

Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx IGH Assay

NCT06112301

Therapeutic Areas

Hematologic Diseases 1

What is open in the Invivoscribe pipeline

1 recruiting of 3 indexed (33% open); 1 completed (33%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Hematologic Diseases (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Invivoscribe: open-pipeline peers nationwide

Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Invivoscribe sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40% Total trials Recruiting share Invivoscribe10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Invivoscribe sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Invivoscribe sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Invivoscribe page

3 registered trials is a research-attention snapshot, not an endorsement of Invivoscribe or any single study.

  • 1 of Invivoscribe's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hematologic Diseases is the condition Invivoscribe studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hematologic Diseases trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Invivoscribe pipeline card: 3 registered trials from official public datasets.Report a data error.